• EZ Cap™ OVA mRNA in Reliable Cell Assays

  2026-09-24

  A scenario-driven guide to using EZ Cap™ OVA mRNA (SKU R1027) in cell viability, proliferation, cytotoxicity, and gene expression studies. It connects product specifications with practical handling and assay controls, while distinguishing established product data from conditions researchers must optimize in their own systems.

• Mildronate Lipidoids Reduce Inflammation in mRNA Vaccines

  2026-09-24

  A 2024 ACS Nano study describes mildronate-derived cationic lipidoids formulated at low dose in an mRNA lipid nanoparticle, mLNP-69. In preclinical B16OVA melanoma models, the formulation supported mRNA vaccine delivery while reducing local inflammation relative to an SM102-based comparator, motivating further evaluation of delivery systems that balance expression and tolerability.

• Dhcr7 Knockout Grass Carp Show GCRV Resistance

  2026-09-23

  A 2026 study used CRISPR/Cas9 to disrupt dhcr7 in grass carp and found improved survival after GCRV-II challenge, alongside stronger antiviral responses and reduced tissue damage. The results identify Dhcr7 as a candidate for disease-resistance breeding, while leaving open whether chemical DHCR7 inhibition can reproduce the effects of gene disruption.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-09-23

  The reference study developed a new allosteric pyruvate dehydrogenase kinase 4 inhibitor series from an anthraquinone hit and identified compound 8c as a potent lead with an in vitro IC50 of 84 nM. Its metabolic stability, pharmacokinetic behavior, glucose-tolerance benefit, antiallergic activity, and cancer-related cellular effects support PDK4 as a tractable pharmacological target, while also defining important limits for translation.

• ETS1–SENP2 Signaling in Bronchopulmonary Dysplasia

  2026-09-22

  The reference study identifies ETS1 as a transcriptional regulator of mitochondrial quality control in hyperoxia-induced bronchopulmonary dysplasia. Its central mechanism links ETS1-driven SENP2 expression to FUNDC1 deSUMOylation, HSPA8-dependent FUNDC1 degradation, and suppression of excessive mitophagy, providing a mechanistic framework for studying mitochondrial injury in developing lungs.

• ac4C Improves Synthetic mRNA Translation Fidelity

  2026-09-22

  The reference study identifies N4-acetylcytidine (ac4C) as an alternative to m1Ψ that preserves immune suppression while increasing synthetic mRNA protein output. Its experiments connect slower m1Ψ-dependent elongation with ribosome collisions, quality-control activation, and +1 frameshifting, offering a mechanistic framework for designing more reliable mRNA translation assays.

• Mildronate-Derived Lipidoids for mRNA Vaccine Delivery

  2026-09-21

  A 2024 ACS Nano study developed mildronate-derived cationic lipids for low-dose lipid nanoparticles that preserved mRNA delivery while reducing local inflammatory effects. In prophylactic and therapeutic B16OVA melanoma models, the mLNP-69 formulation supported effective cancer vaccine activity, providing a useful preclinical framework for evaluating delivery efficiency and reactogenicity together.

• Firefly Luciferase mRNA Workflow for LNP Assays

  2026-09-21

  Build sensitive, transient reporter assays with Cap1-capped, 5-moUTP-modified Firefly Luciferase mRNA for delivery, translation, viability, and imaging studies. The workflow also shows how a luciferase payload can compare next-generation LNP designs while separating expression performance from inflammatory effects.

• Stable Yeast Expression of Exendin-4: Study Review

  2026-09-20

  Balius et al. designed recombinant expression systems for Exendin-4, also known as Exenatide, in Escherichia coli and Saccharomyces cerevisiae. Chromosomal integration in yeast produced immunoreactive Exendin-4 at the expected size, establishing an early synthetic-biology platform while leaving bioactivity, purification, oral delivery, and therapeutic performance for future studies.

• Firefly Luciferase mRNA Workflow Guide

  2026-09-19

  Build sensitive reporter assays, compare delivery systems, and troubleshoot expression loss with 5-moUTP modified mRNA. This guide connects Cap1-capped Firefly Luciferase mRNA workflows with practical LNP and nebulization decisions while separating validated findings from assay starting points.

• NT5DC2–ACSL3 Control of Ferroptosis in Bladder Cancer

  2026-09-18

  A 2026 Cell Death Discovery study identifies NT5DC2 as a suppressor of ferroptosis in bladder cancer by preventing ACSL3 ubiquitination and maintaining ACSL3 protein stability. The work connects a clinically associated oncogenic factor to post-translational control of ferroptosis and positions the NT5DC2–ACSL3 axis as a mechanistic target for future bladder cancer studies.

• Novel Allosteric PDK4 Inhibitors: Study Analysis

  2026-09-18

  This 2019 Journal of Medicinal Chemistry study optimized an anthraquinone hit into allosteric pyruvate dehydrogenase kinase 4 inhibitors and identified compound 8c as a potent lead. The work connected biochemical activity with metabolic stability, pharmacokinetic assessment, glucose-tolerance testing, allergic-reaction models, and cancer-related cellular assays, while highlighting the lipoamide-binding site as a drug-development opportunity.

• HyperScribe™ mRNA Synthesis Kit II Guide

  2026-09-17

  This guide explains how an mRNA synthesis kit based on T7 transcription, an EZ Cap reagent with 3′ OMe chemistry, and poly(A) production can support preclinical mRNA workflows. HyperScribe™ K1066 is a research-use reagent system, not a validated treatment for intervertebral disc degeneration.

• Promethazine HCl in Macrophage Host-Defense Assays

  2026-09-17

  Promethazine HCl provides a practical probe for connecting H1-receptor biology with macrophage ROS, lysosomal activity, and autophagy workflows. Its value is greatest when receptor-proximal signaling, host-defense phenotypes, and compound-related assay interference are measured as separate experimental layers.

• Pexmetinib (ARRY-614) Assay Workflow Guide

  2026-09-16

  Pexmetinib (ARRY-614) combines p38 MAPK and Tie2/Tek inhibition for inflammation, cytokine, and bone-marrow signaling studies. This practical guide connects concentration selection with phospho-protein, cytokine, and matrix-specific controls for more interpretable results.

8526 records 1/569 page Next 12345 下5页 Last page